Previous Close | 7.56 |
Open | 7.58 |
Bid | 7.37 x 2900 |
Ask | 7.64 x 800 |
Day's Range | 7.23 - 7.71 |
52 Week Range | 5.64 - 14.30 |
Volume | |
Avg. Volume | 866,177 |
Market Cap | 589.172M |
Beta (5Y Monthly) | 1.11 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.11 |
Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.70 |
Subscribe to Yahoo Finance Plus to view Fair Value for GOSS
SAN DIEGO, June 09, 2022--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the publication of key preclinical data supporting the potential of seralutinib for the treatment of pulmonary arterial hypertension (PAH). The article, entitled "Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arteria
The mean of analysts' price targets for Gossamer Bio (GOSS) points to an 113.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
After losing some value lately, a hammer chart pattern has been formed for Gossamer Bio (GOSS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.